Welcome to our dedicated page for Nanoviricides news (Ticker: NNVC), a resource for investors and traders seeking the latest updates and insights on Nanoviricides stock.
NanoViricides, Inc. (NNVC) generates frequent news as a clinical stage biotechnology company focused on nanomedicine-based antiviral drug candidates. Its updates center on the development and regulatory progress of NV-387, a broad-spectrum antiviral that the company states is designed to mimic host cell attachment receptors such as sulfated proteoglycans, aiming to trap and neutralize a wide range of human pathogenic viruses.
News coverage for NanoViricides often highlights clinical and regulatory milestones. Recent announcements include approval by the regulatory agency ACOREP in the Democratic Republic of Congo to start a Phase II clinical trial of NV-387 for MPox, ongoing work toward a Phase II trial for viral acute and severe acute respiratory infections (viral ARI/SARI), and preparations for orphan drug designation applications for MPox, Smallpox, and Measles. The company also reports on its Phase I safety results for NV-387 and describes its efforts to advance NV-387 into Phase II human clinical trials.
Investors and observers following NNVC news can expect detailed discussions of preclinical and clinical data in animal models and early human studies, including comparisons of NV-387 to existing antivirals such as oseltamivir, baloxavir, peramivir, remdesivir, and tecovirimat. Press releases frequently address emerging viral threats, such as influenza A/H3N2 variants, H5N1 bird flu, MPox clades, coronaviruses, RSV, and Measles, and position NV-387 within these contexts.
NanoViricides also issues news on financing events, such as registered direct offerings and concurrent private placements, which support its research and development plans. Additional coverage includes presentations at investor and partnering conferences, shareholder meeting announcements, and commentary from company leadership on the potential role of nanoviricide technology in pandemic preparedness and bioterrorism response. Bookmark this page to review ongoing NNVC news as the company reports new data, regulatory interactions, and corporate developments.
NanoViricides, Inc. (NYSE American:NNVC) announces participation in the EF Hutton Annual Global Conference on May 15, 2024, in New York City. The Company's President will discuss progress, particularly the promising antiviral drug NV-387. Successful completion of Phase 1a/1b clinical trials with no adverse events on healthy subjects indicates excellent safety. NV-387 demonstrates strong antiviral activity against various viruses and could potentially treat Coronaviruses, RSV, and Influenza A. Plans for Phase II trials and a pipeline of drug candidates are underway.
NanoViricides, Inc. announces NV-387, a novel broad-spectrum antiviral with activity against Smallpox/Mpox. NV-387 shows strong orthopoxvirus activity against Smallpox/Mpox, both inhalation and skin abrasion modes. Animal studies demonstrate increased survival compared to tecovirimat, approved for Smallpox. NV-387 potentially reduces tecovirimat resistance. NanoViricides focuses on developing antiviral nanomedicines for various viral infections.
NanoViricides, Inc. announces the development of NV-387, a broad-spectrum antiviral drug with strong activity against Influenza A viruses, potentially including Bird Flu H5N1 virus. In a study, NV-387 showed superior antiviral effects compared to three approved anti-influenza drugs. The company believes that NV-387 may have significant potential in treating various respiratory viruses.
NanoViricides, Inc. (NNVC) reports successful completion of Phase I NV-387 Clinical Trial in India. NV-387 has shown broad-spectrum antiviral activity against various viruses. Data lock is expected soon for further analysis. Plans for Phase II trials in progress, targeting RSV infections in adults, infants, and children. The potential market size for RSV therapeutics is estimated at $8.73 billion by 2031. NanoViricides' platform technology reduces the likelihood of viruses escaping treatment.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.